Immuron gets go-ahead for finalisation of IMM-124E trials
Published on: | by Trevor Hoey
Shares in Immuron (ASX: IMC) traded nearly 7% higher on Monday morning after the company released positive interim results regarding the safety and efficacy of its ongoing IMM-124E Phase II study in non-alcoholic steatohepatitis (NASH).
Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
The objectives of the analysis were to establish the safety of the compound and to provide a preliminary read on efficacy signals. The trial enrolled 133 patients with the top line results expected in the fourth quarter of 2017.
These positive outcomes are extremely important given that they demonstrate that the IMM-124E compound is non-absorbable, safe and tolerable. Early biochemical improvements in liver enzymes were also noted, suggesting potential therapeutic benefits for the treatment of NASH.
The upshot of these developments has been a recommendation to continue the trial to completion given there is no concern for safety or futility.
Commenting on this development, IMC’s Chief Executive Thomas Liquard said, “NASH is increasingly viewed as a multifactorial disease whereby the approval of several chronic therapies with different MOAs and used in combination, will be needed to control its long-term effects”.
Liquard also noted that the results support the company’s belief that IMM-124E is a compound with a complex MOA that has the potential to have a beneficial impact in hard to treat fatty liver diseases.